Iovance Biotherapeutics Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for mNSCLC

Iovance Biotherapeutics announced updated results from its Phase 2 IOV-LUN-202 trial for lifileucel in non-small cell lung cancer and introduced a new biomarker-enriched precision TIL strategy.